EGFR and breast cancer: Other genes showed relatively lower alteration frequencies in CMTs than in human breast cancers, including TP53 (inactivated in 0%, 15%, and 48% of benign CMTs, malignant CMTs, and human breast cancers, respectively), as well as EGFR, ERBB2, ATM, and CHEK2. In addition, AKT3, MDM2, and MDM4 were rarely altered in CMTs.